Muutke küpsiste eelistusi

Navigating Pediatric Brain Tumors [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 442 pages, kõrgus x laius: 254x178 mm, 79 Illustrations, color; 36 Illustrations, black and white
  • Ilmumisaeg: 08-Jun-2026
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 3032189918
  • ISBN-13: 9783032189912
Teised raamatud teemal:
  • Kõva köide
  • Hind: 169,31 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 199,19 €
  • Säästad 15%
  • See raamat ei ole veel ilmunud. Raamatu kohalejõudmiseks kulub orienteeruvalt 3-4 nädalat peale raamatu väljaandmist.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 442 pages, kõrgus x laius: 254x178 mm, 79 Illustrations, color; 36 Illustrations, black and white
  • Ilmumisaeg: 08-Jun-2026
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 3032189918
  • ISBN-13: 9783032189912
Teised raamatud teemal:
Tumors of the central nervous system (CNS) pose a significant health challenge due to their high morbidity and mortality rates across all ages. In children, brain tumors are the second most commonly diagnosed cancer worldwide, accounting for approximately a quarter of childhood cancers. Despite moderate increases in survival rates for children with CNS tumors in recent decades, these tumors remain the second leading cause of cancer death in children under 20, requiring a multidisciplinary approach.



The World Health Organization (WHO) has recently published the fifth edition of its Classification of Tumors of the Central Nervous System (WHO CNS5). This updated framework incorporates molecular data alongside histology to classify CNS tumors, grouping them into entities that are more biologically and molecularly defined, with better-characterized natural histories. The classification introduces new tumor types and subtypes, particularly in the pediatric population.



This book provides a thorough overview of how to manage pediatric central nervous system tumors, offering not only a detailed analysis of the medical aspects of CNS tumors but also guidance on how families and caregivers can cope with the disease. It also presents a detailed analysis of the molecular landscape of these tumors, including the role of molecular testing in diagnosing and monitoring these tumors, as well as the challenges and limitations of implementing such analyses in clinical practice.



The book is further enriched by personal stories from children and families affected by the disease and includes practical advice on navigating the healthcare system, along with resources for emotional support. Last but not least, it also explores emerging innovative therapeutic strategies, including immunotherapy, gene therapy, and targeted drug therapies, addressing their application in pediatric CNS tumors as well as associated challenges, ethical considerations, and regulatory hurdles.



This text will serve as an invaluable resource for physicians, researchers, patient advocates, and other healthcare professionals involved in the treatment and support of children affected by CNS tumors and their families.
1. Epidemiology.-
2. Clinical presentation and diagnosis.-
3.
Neuroimaging.-
4. Pathology and molecular biology.-
5. Cancer predisposition
syndromes.-
6. Principles of neurosurgery.-
7. Principles of radiation
oncology.-
8. Principles of medical treatment.-
9. Principles of
immunotherapy.-
10. Medulloblastoma.-
11. AT/RT.-
12. Rare embryonal tumors.-
13. Ependymoma.-
14. Post-operative cerebellar mutism syndrome/posterior
fossa syndrome: .-
15. Pediatric low-grade glioma.-
16. Pediatric high-grade
glioma.-
17. Germ cell tumors.-
18. Craniopharyngioma.-
19. Rare tumors.-
20.
Spinal cord tumors.-
21. Long-term follow-up and quality of life.-
22.
Supportive care and rehabilitation:.-
23. Palliative care and end-of-life
considerations.-
24. Patient organizations and advocacy.
Prof. Angela Mastronuzzi is Head of the Neuro-Oncology Unit within the Department of Hematology-Oncology, Cell Therapy, Gene Therapies and Hematopoietic Transplantation at Bambino Gesù Childrens Hospital in Rome. She is Associate Professor of General and Specialized Pediatrics at Università Cattolica del Sacro Cuore and teaches in several Masters and PhD programs at Sapienza University of Rome. She is also President of AIEOP, the Italian Association of Pediatric Hematology-Oncology. Her clinical activity focuses on pediatric central nervous system tumors and cancer predisposition syndromes, with extensive expertise in innovative therapies, including phase I trials, targeted therapy, cell therapy and gene therapy. Prof. Mastronuzzi has led or contributed to over 50 phase I/II/III clinical trials and protocols. Her research focuses on precision medicine and artificial intelligence in pediatric cancer, within major EU-funded projects.  Dr. Andrea Carai, PhD, MD, is Chief of the Neurosurgery Unit at Bambino Gesù Childrens Hospital in Rome, actively collaborating with the Neuro-Oncology Unit. He studied medicine at the University of Sassari; later completed his neurosurgery residency at the same university in 2007 and his PhD fellowship in biomedical sciences with a focus on the nervous system in 2011. He served as a research fellow in 2009 and as visiting professor in 2012 at the Neurosurgery Department of the Mount Sinai Hospital in New York City. In 2018 he received a masters degree in Pediatric Neurology and in 2020 a masters degree in Management and Direction of Healthcare Companies. Dr. Carai's main interests include innovative intraoperative visualization solutions (fluorescence assisted surgery, intraoperative imaging, image guided surgery), integration of virtual reality and simulation in the clinical practice and reduction of neurosurgical morbidity for the improvement of quality of life of children from the neurosurgical perspective. He is passionate about innovation and his work in clinical research. He is a Board Member and Chair of the Special Interest Group Neurosurgery of the Posterior Fossa Society (SNO) and member of the SIOP-E Brain Tumor Working Group -Neurosurgery.